Lurasidone Hydrochloride CAS 367514-88-3 Purity ≥99.0% API Factory High Purity

Chemical Name: Lurasidone Hydrochloride Synonyms: Lurasidone HCl; Latuda CAS: 367514-88-3 Appearance: White or Off-White Crystalline Powder Purity: ≥99.0%   An antipsychotic used for treatment of schizophrenia. API High Quality, Commercial Production E-mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply Lurasidone Hydrochloride Related Intermediates: (1R,2R)-1,2-Cyclohexanedimethanol CAS 65376-05-8  (3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione CAS 14805-29-9  Lurasidone Hydrochloride CAS 367514-88-3 API 
Item Specifications
Appearance White or Off-White Crystalline Powder
NMR Consistent with Structure
Solubility Meets the Requirements
Max. Single Impurity ≤0.20%
Total Impurities ≤0.50%
Moisture (K.F) ≤1.0%
Residue of Ignition ≤0.20%
Heavy Metals ≤20ppm
Purity ≥99.0% 
Test Standard Enterprise Standard
Usage API,  Atypical Antipsychotic Drug (AAPD)

Description:

Specifications:

Package & Storage:

Chemical Name Lurasidone Hydrochloride
Synonyms Lurasidone HCl; Latuda
CAS Number 367514-88-3
CAT Number RF-API64
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C28H36N4O2S
Molecular Weight 492.684
Melting Point 198.0~205.0°C
Shipping Condition Shipped Under Ambient Temperature
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Lurasidone Hydrochloride (CAS 367514-88-3) with high quality, API.  Lurasidone Hydrochloride (CAS 367514-88-3) is an orally administered substance that belongs to the class of atypical antipsychotic drugs (AAPD), developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. It received approval by the EMA in 2014 for schizophrenia. Lurasidone has also been launched in a number of countries outside the US and EU, including Canada, where it is approved for both indications. It is produced through a multi-step chemical process.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours